Gabriel Sjölin1, Mats Holmberg2,3, Ove Törring4, Kristina Byström5, Selwan Khamisi6,7, Dorota de Laval8, Mirna Abraham-Nordling9, Jan Calissendorff9,10, Mikael Lantz11,12, Bengt Hallengren11,12, Helena Filipsson Nyström2,13, Göran Wallin1,9. 1. Department of Surgery, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. 2. Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden. 3. ANOVA, Karolinska University Hospital, Stockholm, Sweden. 4. Institution for Clinical Science and Education, Karolinska Institutet and Division of Endocrinology, Department of Internal Medicine, Södersjukhuset, Stockholm, Sweden. 5. Department of Medicine, Örebro University and University Hospital, Örebro, Sweden. 6. Department of Endocrinology, Uppsala University Hospital, Uppsala, Sweden. 7. Department of Medical Sciences, Uppsala University, Uppsala, Sweden. 8. Department of Medicine, Blekinge Hospital, Karlskrona, Sweden. 9. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. 10. Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden. 11. Department of Endocrinology, Skåne University Hospital, Malmö, Sweden. 12. Department of Clinical Sciences, Lund University, Lund, Sweden. 13. Department of Endocrinology, Sahlgrenska University Hospital, Göteborg, Sweden.
Abstract
Background: The treatment efficacy of antithyroid drug (ATD) therapy, radioactive iodine (131I), or surgery for Graves' hyperthyroidism is well described. However, there are a few reports on the long-term total outcome of each treatment modality regarding how many require levothyroxine supplementation, the need of thyroid ablation, or the individual patient's estimation of their recovery. Methods: We conducted a pragmatic trial to determine the effectiveness and adverse outcome in a patient cohort newly diagnosed with Graves' hyperthyroidism between 2003 and 2005 (n = 2430). The patients were invited to participate in a longitudinal study spanning 8 ± 0.9 years (mean ± standard deviation) after diagnosis. We were able to follow 1186 (60%) patients who had been treated with ATD, 131I, or surgery. We determined the mode of treatment, remission rate, recurrence, quality of life, demographic data, comorbidities, and lifestyle factors through questionnaires and a review of the individual's medical history records. Results: At follow-up, the remission rate after first-line treatment choice with ATD was 45.3% (351/774), with 131I therapy 81.5% (324/264), and with surgery 96.3% (52/54). Among those patients who had a second course of ATD, 29.4% achieved remission (vs. the 45.3% after the first course of ATD). The total number of patients who had undergone ablative treatment was 64.3% (763/1186), of whom 23% (278/1186) had received surgery, 43% (505/1186) had received 131I therapy, including 2% (20/1186) who had received both surgery and 131I. Patients who received ATD as first-line treatment and possibly additional ATD had 49.7% risk (385/774) of having undergone ablative treatment at follow-up. Levothyroxine replacement was needed in 23% (81/351) of the initially ATD treated in remission, in 77.3% (204/264) of the 131I treated, and in 96.2% (50/52) of the surgically treated patients. Taken together after 6-10 years, and all treatment considered, normal thyroid hormone status without thyroxine supplementation was only achieved in 35.7% (423/1186) of all patients and in only 40.3% of those initially treated with ATD. The proportion of patients that did not feel fully recovered at follow-up was 25.3%. Conclusion: A patient selecting ATD therapy as the initial approach in the treatment of Graves' hyperthyroidism should be informed that they have only a 50.3% chance of ultimately avoiding ablative treatment and only a 40% chance of eventually being euthyroid without thyroid medication. Surprisingly, 1 in 4 patients did not feel fully recovered after 6-10 years. The treatment for Graves' hyperthyroidism, thus, has unexpected long-term consequences for many patients.
Background: The treatment efficacy of antithyroid drug (ATD) therapy, radioactive iodine (131I), or surgery for Graves' hyperthyroidism is well described. However, there are a few reports on the long-term total outcome of each treatment modality regarding how many require levothyroxine supplementation, the need of thyroid ablation, or the individual patient's estimation of their recovery. Methods: We conducted a pragmatic trial to determine the effectiveness and adverse outcome in a patient cohort newly diagnosed with Graves' hyperthyroidism between 2003 and 2005 (n = 2430). The patients were invited to participate in a longitudinal study spanning 8 ± 0.9 years (mean ± standard deviation) after diagnosis. We were able to follow 1186 (60%) patients who had been treated with ATD, 131I, or surgery. We determined the mode of treatment, remission rate, recurrence, quality of life, demographic data, comorbidities, and lifestyle factors through questionnaires and a review of the individual's medical history records. Results: At follow-up, the remission rate after first-line treatment choice with ATD was 45.3% (351/774), with 131I therapy 81.5% (324/264), and with surgery 96.3% (52/54). Among those patients who had a second course of ATD, 29.4% achieved remission (vs. the 45.3% after the first course of ATD). The total number of patients who had undergone ablative treatment was 64.3% (763/1186), of whom 23% (278/1186) had received surgery, 43% (505/1186) had received 131I therapy, including 2% (20/1186) who had received both surgery and 131I. Patients who received ATD as first-line treatment and possibly additional ATD had 49.7% risk (385/774) of having undergone ablative treatment at follow-up. Levothyroxine replacement was needed in 23% (81/351) of the initially ATD treated in remission, in 77.3% (204/264) of the 131I treated, and in 96.2% (50/52) of the surgically treated patients. Taken together after 6-10 years, and all treatment considered, normal thyroid hormone status without thyroxine supplementation was only achieved in 35.7% (423/1186) of all patients and in only 40.3% of those initially treated with ATD. The proportion of patients that did not feel fully recovered at follow-up was 25.3%. Conclusion: A patient selecting ATD therapy as the initial approach in the treatment of Graves' hyperthyroidism should be informed that they have only a 50.3% chance of ultimately avoiding ablative treatment and only a 40% chance of eventually being euthyroid without thyroid medication. Surprisingly, 1 in 4 patients did not feel fully recovered after 6-10 years. The treatment for Graves' hyperthyroidism, thus, has unexpected long-term consequences for many patients.
Authors: K V Derkach; E A Fokina; A A Bakhtyukov; V N Sorokoumov; A M Stepochkina; I O Zakharova; A O Shpakov Journal: Bull Exp Biol Med Date: 2022-05-02 Impact factor: 0.804
Authors: Verena Theiler-Schwetz; Thomas Benninger; Christian Trummer; Stefan Pilz; Markus Reichhartinger Journal: Front Endocrinol (Lausanne) Date: 2022-05-31 Impact factor: 6.055
Authors: Lian Duan; Han-Yu Zhang; Min Lv; Han Zhang; Yao Chen; Ting Wang; Yan Li; Yan Wu; Junfeng Li; Kefeng Li Journal: Endocr Connect Date: 2022-05-27 Impact factor: 3.221
Authors: Jelte van der Vaart; Lynn Bosmans; Stijn F Sijbesma; Kèvin Knoops; Willine J van de Wetering; Henny G Otten; Harry Begthel; Inne H M Borel Rinkes; Jeroen Korving; Eef G W M Lentjes; Carmen Lopez-Iglesias; Peter J Peters; Hanneke M van Santen; Menno R Vriens; Hans Clevers Journal: Proc Natl Acad Sci U S A Date: 2021-12-21 Impact factor: 11.205
Authors: Sadaf Mohtashami; Keith Richardson; Veronique-Isabelle Forest; Alex Mlynarek; Richard J Payne; Michael Tamilia; Marc P Pusztaszeri; Michael P Hier; Nader Sadeghi; Marco A Mascarella Journal: Ann Otol Rhinol Laryngol Date: 2021-06-01 Impact factor: 1.547